Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07314905
PHASE3

Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)

Sponsor: Unity Health Toronto

View on ClinicalTrials.gov

Summary

TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens in non-hospitalized patients. Participants will be randomized to receive usual care (i.e., supportive care and symptom relief) or a study therapeutic, which will be determined by the TreatResp Therapeutics Committee. The primary outcomes being evaluated is time to recovery.

Official title: Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

264

Start Date

2026-01-02

Completion Date

2027-04-24

Last Updated

2026-01-02

Healthy Volunteers

No

Interventions

DRUG

Baloxavir

This is a sub-protocol within the TreatResp adaptive platform trial to compare the clinical and cost-effectiveness of Baloxavir, a single 40mg or 80 mg tablet based on patient weight, to a matching placebo among non-hospitalized patients with mild to moderate influenza A/B. This sub-protocol is part of the influenza domain within TreatResp.

DRUG

Placebo Control

Matching placebo for Baloxavir

Locations (1)

Unity Health Toronto

Toronto, Ontario, Canada